Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar;25(3):463-470.
doi: 10.1016/j.ajt.2024.11.011. Epub 2024 Nov 16.

The role of induction therapy in lung transplantation

Samantha M Landino  1 , James T Nawalaniec  1 , Nicole Hays  1 , Asishana A Osho  2 , Brian C Keller  3 , James S Allan  4 , Shaf Keshavjee  5 , Joren C Madsen  6 , Ramsey Hachem  7
Affiliations
Review

The role of induction therapy in lung transplantation

Samantha M Landino et al. Am J Transplant. 2025 Mar.

Abstract

Induction immunosuppression in solid organ transplantation involves a short course of potent immunosuppression in the perioperative period, with the goal of preventing early acute rejection and delaying initiation or reducing the dose of calcineurin inhibitors to minimize kidney injury. The use of induction immunosuppression in lung transplantation has increased over time, with over 80% of adult lung transplant recipients receiving some form of induction therapy. Currently, more than 70% of lung transplant recipients receive induction with an interleukin-2 receptor antagonist, and basiliximab is the most used agent. Despite this now common practice, the evidence to support and guide induction immunosuppression following lung transplantation is limited, making the use of induction somewhat controversial. Here, we review the available literature addressing the use of induction immunosuppression in lung transplant recipients.

Keywords: IL-2 receptor antagonist; basiliximab; induction immunosuppression; lung transplantation.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

References

    1. Chambers DC, Cherikh WS, Harhay MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019;38(10):1042–1055. - PMC - PubMed
    1. Shagabayeva L, Osho AA, Moonsamy P, et al. Induction therapy in lung transplantation: A contemporary analysis of trends and outcomes. Clin Transplant. 2022;36(11):e14782. - PubMed
    1. Valapour M, Lehr CJ, Schladt DP, et al. OPTN/SRTR 2022 Annual Data Report: Lung. Am J Transplant. 2024;24(2S1):S394–S456. - PubMed
    1. Small B, Au J, Brink H, Shah I, Strah H. Induction and maintenance immunosuppression in lung transplantation. Indian J Thorac Cardiovasc Surg. 2022;38(Suppl 2):300–317. - PMC - PubMed
    1. Hayes D Jr., Black SM, Tobias JD, et al. Influence of human leukocyte antigen mismatching on bronchiolitis obliterans syndrome in lung transplantation. J Heart Lung Transplant. 2016;35(2):186–194. - PubMed

MeSH terms

Substances

LinkOut - more resources